我们能治愈抗脂综合征吗?
Pier Luigi Meroni1, Enrico Capobianco2, Francesco Tedesco1
1Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Current opinion in immunology
|August 6, 2025
概括
抗脂抗体综合征 (APS) 涉及由于特定的自身抗体而导致的凝血和流产. 目前的治疗方法不足,需要针对自身抗体生产的新疗法,以更好地管理APS.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 血管生物学 血管生物学
背景情况:
- 抗脂抗体综合征 (APS) 的特征是复发性血栓形成和怀孕流产.
- 病理是由对脂结合蛋白 (aPL) 的自身抗体介导的,主要是β2糖蛋白I (β2GPI).
- 目前的治疗方法,如抗凝血剂和抗血小板药物,并不普遍有效,导致治疗复发.
研究的目的:
- 审查目前对APS病理生理学和治疗局限性的理解.
- 探索针对自身抗体产生和免疫机制的新疗法.
- 确定未来的研究方向,以改善APS管理和潜在的治疗方法.
主要方法:
- 文献综述和APS当前研究的综合.
- 分析现有和新兴的治疗目标和策略.
- 讨论与新型APS治疗相关的临床前和临床发现.
主要成果:
- 标准的抗凝血剂和抗血小板疗法在预防APS相关事件方面存在局限性.
- 传统的免疫抑制和B细胞疗法在抑制aPL方面没有被证明有效.
- 新兴的策略,如向CD38,抗CD19的CAR-T细胞疗法和仿真自身抗原受体T细胞疗法,显示出有前途.
结论:
- 迫切需要更有效的APS疗法,超出目前的护理标准.
- 针对自身抗体产生细胞,特别是通过基于T细胞的免疫疗法,是一个有前途的途径.
- 对凝块溶解和β2GPI/抗β2GPI相互作用的进一步研究可能会产生新的临床前治疗方法.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Anticoagulant Drugs: Low-Molecular-Weight Heparins
909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


